{"id":35018,"date":"2026-07-28T17:05:22","date_gmt":"2026-07-28T11:35:22","guid":{"rendered":"https:\/\/fundsindia.com\/blog\/?p=35018"},"modified":"2026-07-28T17:20:51","modified_gmt":"2026-07-28T11:50:51","slug":"manipal-health-enterprises-ipo-note-equity-research-desk","status":"publish","type":"post","link":"https:\/\/www.fundsindia.com\/blog\/equities\/manipal-health-enterprises-ipo-note-equity-research-desk\/35018","title":{"rendered":"Manipal Health Enterprises &#8211; IPO Note &#8211; Equity Research Desk"},"content":{"rendered":"\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/07\/1-IPOs-Push.jpg\"><img loading=\"lazy\" width=\"1024\" height=\"512\" src=\"https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/07\/1-IPOs-Push.jpg\" alt=\"\" class=\"wp-image-35021\" srcset=\"https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2026\/07\/1-IPOs-Push.jpg 1024w, https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2026\/07\/1-IPOs-Push-300x150.jpg 300w, https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2026\/07\/1-IPOs-Push-768x384.jpg 768w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<h2><strong><span class=\"has-inline-color has-vivid-cyan-blue-color\">Company Overview<\/span><\/strong><\/h2>\n\n\n\n<p>Manipal Health Enterprises Limited is a pan-India multispecialty hospital operator, running 49 hospitals with 13,037 licensed beds across 14 states and union territories as of March 31, 2026. Its network is concentrated in three key regions \u2014 Karnataka, Maharashtra and Goa, and select states of eastern India (West Bengal, Odisha, Jharkhand and Sikkim) \u2014 and spans the metros of Bengaluru, Kolkata and Pune alongside a wide non-metro presence, with the bed base split 46.78% metro and 53.22% non-metro.<\/p>\n\n\n\n<p>The Company served 7.63 million patients across its network in Fiscal 2026 and had 11,064 doctors and 24,240 employees as of March 31, 2026. Its clinical services are focused on tertiary and quaternary care across cardiac sciences, oncology, neurosciences, gastro sciences, orthopedics and renal sciences, which contributed 64.30% of gross inpatient revenue in Fiscal 2026, and 41 of its 49 hospitals were NABH-accredited. Growth has come through a mix of organic expansion and strategic acquisitions \u2014 including AMRI (2023), Medica Synergie (2024) and the Sahyadri Group (October 2025) \u2014 with the network expanding from 33 hospitals and 9,520 licensed beds as of March 31, 2024 to 49 hospitals and 13,037 licensed beds as of March 31, 2026.<\/p>\n\n\n\n<h2><strong><span class=\"has-inline-color has-vivid-cyan-blue-color\">Offer Summary<\/span><\/strong><\/h2>\n\n\n\n<p>The Company is undertaking a book-built issue at a price band of \u20b9560 to \u20b9590 per Equity Share, comprising a Fresh Issue of 13,55,93,220&nbsp;shares, aggregating up to \u20b98,000.00 crore and an Offer for Sale of up to 21,613,834 Equity Shares of face value of \u20b92 each by the Selling Shareholders aggregating up to \u20b91,275.22 crore.<\/p>\n\n\n\n<h2><strong><span class=\"has-inline-color has-vivid-cyan-blue-color\">Objects of the Offer<\/span><\/strong><\/h2>\n\n\n\n<ul><li>Repayment or prepayment, in full or in part, of certain outstanding borrowings and accrued interest thereon availed by the Company\u2019s Material Subsidiary, Manipal Hospitals Private Limited. (\u20b95,552.76 crore from the Net Proceeds of the Fresh Issue, representing approximately 47.47% of the Company\u2019s total consolidated outstanding borrowings as at May 31, 2026)<\/li><li>Acquisition of a minority stake in the Company\u2019s stepdown Subsidiary, Sahyadri Hospitals Private Limited \u2014 \u20b9574.00 crore; and<\/li><li>General corporate purposes (not exceeding 25% of the gross proceeds of the Fresh Issue).<\/li><\/ul>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/07\/1-IPOs_Blog-Banner-1-3.jpg\"><img loading=\"lazy\" width=\"1024\" height=\"722\" src=\"https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/07\/1-IPOs_Blog-Banner-1-3-1024x722.jpg\" alt=\"\" class=\"wp-image-35022\" srcset=\"https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2026\/07\/1-IPOs_Blog-Banner-1-3-1024x722.jpg 1024w, https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2026\/07\/1-IPOs_Blog-Banner-1-3-300x211.jpg 300w, https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2026\/07\/1-IPOs_Blog-Banner-1-3-768x541.jpg 768w, https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2026\/07\/1-IPOs_Blog-Banner-1-3-1536x1082.jpg 1536w, https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2026\/07\/1-IPOs_Blog-Banner-1-3-2048x1443.jpg 2048w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<h2><strong><span class=\"has-inline-color has-vivid-cyan-blue-color\">Industry Snapshot<\/span><\/strong><\/h2>\n\n\n\n<p>The Company operates in the Indian healthcare delivery market, which comprises In-patient Department (\u201cIPD\u201d) and Out-patient Department (\u201cOPD\u201d) services provided by both government and private players, with IPD contributing the bulk of industry revenue. According to the CRISIL Report, the market was valued at approximately \u20b97.0 trillion in Fiscal 2025 and is estimated to have reached \u20b97.6\u20137.8 trillion in Fiscal 2026, with the IPD segment accounting for 71\u201372% of value. The market is projected to grow at a CAGR of 10\u201312% between Fiscal 2025 and Fiscal 2030 to reach \u20b911.2\u201312.2 trillion, with IPD growing faster at 10.5\u201312.5% and OPD at 8\u201310%. The market remains highly fragmented, with large private hospitals accounting for only about 20% of the overall market in Fiscal 2026, and the private sector\u2019s share of treatments by value is expected to rise from 64% in Fiscal 2020 to approximately 69% by Fiscal 2030. Cardiac sciences (17%) and oncology (12%) are the largest single-specialty segments.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/07\/image-45.png\"><img loading=\"lazy\" width=\"823\" height=\"416\" src=\"https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/07\/image-45.png\" alt=\"\" class=\"wp-image-35023\" srcset=\"https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2026\/07\/image-45.png 823w, https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2026\/07\/image-45-300x152.png 300w, https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2026\/07\/image-45-768x388.png 768w\" sizes=\"(max-width: 823px) 100vw, 823px\" \/><\/a><\/figure>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/07\/image-46.png\"><img loading=\"lazy\" width=\"743\" height=\"365\" src=\"https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/07\/image-46.png\" alt=\"\" class=\"wp-image-35024\" srcset=\"https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2026\/07\/image-46.png 743w, https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2026\/07\/image-46-300x147.png 300w\" sizes=\"(max-width: 743px) 100vw, 743px\" \/><\/a><\/figure>\n\n\n\n<p>Key structural growth drivers for the industry include:<\/p>\n\n\n\n<ul><li><strong>Rising chronic-disease burden and ageing demographics: <\/strong>the share of India\u2019s population aged 60 and above is projected to rise from 10.5% in CY2023 to 12.6% by CY2030, and the 40\u201359 cohort from 22.1% to 24.4%, while the incidence of non-communicable diseases is expected to keep rising through Fiscal 2030 \u2014 lifting demand for tertiary, quaternary and geriatric care.<\/li><li><strong>Rising incomes, health awareness and insurance coverage: <\/strong>growing disposable incomes (the share of households in the \u20b9150,000\u2013200,000 annual income bracket rose to 40% in Fiscal 2024), improving health awareness, and health-insurance penetration of 41% in Fiscal 2024 alongside a steady decline in out-of-pocket expenditure as a share of current health expenditure, are together widening affordability and access to quality care.<\/li><li><strong>Structural shift toward private providers, aided by government initiatives: <\/strong>India\u2019s bed density of about 16 hospital beds per 10,000 people in Fiscal 2025 remains well below the global average of 33, underscoring the expansion runway, while schemes such as PMJAY and the Ayushman Bharat Digital Mission (ABDM), coupled with overburdened public infrastructure, are expected to channel an increasing share of demand to private players.<\/li><\/ul>\n\n\n\n<h2><strong><span class=\"has-inline-color has-vivid-cyan-blue-color\">Investment Rationale<\/span><\/strong><\/h2>\n\n\n\n<p><strong>India\u2019s largest hospital network by bed capacity with entrenched regional and metro leadership<\/strong><\/p>\n\n\n\n<p>Manipal ranks #1 among private hospital chains by bed capacity and #2 by number of hospitals, and reported the second-highest revenue from operations in Fiscal 2026. It has the widest hospital footprint of any private chain, holds the leading position in each of its three key regions, and is the only private chain to lead by bed capacity across three metros \u2014 advantages built on scale, density and referral reach that are capital-intensive and difficult to replicate.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/07\/image-47.png\"><img loading=\"lazy\" width=\"815\" height=\"225\" src=\"https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/07\/image-47.png\" alt=\"\" class=\"wp-image-35025\" srcset=\"https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2026\/07\/image-47.png 815w, https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2026\/07\/image-47-300x83.png 300w, https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2026\/07\/image-47-768x212.png 768w\" sizes=\"(max-width: 815px) 100vw, 815px\" \/><\/a><\/figure>\n\n\n\n<p><strong>Diversified across high-acuity specialties, geographies and payors<\/strong><\/p>\n\n\n\n<p>Revenue is spread across a broad specialty base while anchored in complex, high-value care: CONGO-R specialties (cardiac sciences, oncology, neurosciences, gastro sciences, orthopedics and renal sciences) contributed 64.30% of gross inpatient revenue in Fiscal 2026, with no single specialty dominating. The network is balanced across metros (46.78% of licensed beds) and non-metros (53.22%), the latter offering higher-growth, under-penetrated catchments. The payor mix is also diversified \u2014 TPA\/insurance 49.68%, cash 30.33%, government 13.80% and others 6.19% of gross inpatient revenue in Fiscal 2026 \u2014 which, alongside disciplined working-capital management, supported a negative working-capital cycle of 13 days in Fiscal 2026. In practice, this spread insulates revenue from any single specialty, city or payor shock, while the CONGO-R skew keeps the mix anchored to the most profitable, fastest-growing procedures.<\/p>\n\n\n\n<p><strong>Proven, repeatable acquisition-and-integration playbook driving sector-leading growth<\/strong><\/p>\n\n\n\n<p>Between March 31, 2021 and March 31, 2026, Manipal was the leading consolidator among private hospital chains by beds added through acquisitions (5,548 beds), and it has a track record of upgrading acquired assets by deepening high-acuity services and instituting disciplined operating practices. This is visible in the margin uplift achieved post-acquisition, illustrated below, and underpinned the company\u2019s industry-leading revenue growth over Fiscal 2024\u2013Fiscal 2026.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/07\/image-48.png\"><img loading=\"lazy\" width=\"810\" height=\"154\" src=\"https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/07\/image-48.png\" alt=\"\" class=\"wp-image-35026\" srcset=\"https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2026\/07\/image-48.png 810w, https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2026\/07\/image-48-300x57.png 300w, https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2026\/07\/image-48-768x146.png 768w\" sizes=\"(max-width: 810px) 100vw, 810px\" \/><\/a><\/figure>\n\n\n\n<p><strong>Financial Performance<\/strong><\/p>\n\n\n\n<p>Revenue from operations grew at a CAGR of 29.41% over Fiscal 2024\u2013Fiscal 2026 to \u20b910,335.75 crore, and EBITDA (excluding exceptional items) at a CAGR of 25.45% to \u20b92,795.94 crore. Profit after tax, however, declined to \u20b9916.52 crore in Fiscal 2026 from \u20b91,081.67 crore in Fiscal 2025: Fiscal 2025 had benefited from an unusually low tax charge (including a ~\u20b9130 crore deferred-tax credit), while Fiscal 2026 absorbed a ~69% rise in finance costs (to \u20b9864.29 crore) and higher depreciation from debt-funded acquisitions, an exceptional loss, and a normalised tax rate \u2014 compressing PAT margin to 8.87% and RoNW to 10.57%. The \u20b95,552.76 crore of debt repayment planned from Fresh Issue proceeds is expected to materially lower finance costs and support a recovery in returns.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/07\/image-49.png\"><img loading=\"lazy\" width=\"812\" height=\"325\" src=\"https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/07\/image-49.png\" alt=\"\" class=\"wp-image-35027\" srcset=\"https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2026\/07\/image-49.png 812w, https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2026\/07\/image-49-300x120.png 300w, https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2026\/07\/image-49-768x307.png 768w\" sizes=\"(max-width: 812px) 100vw, 812px\" \/><\/a><\/figure>\n\n\n\n<h2><strong><span class=\"has-inline-color has-vivid-cyan-blue-color\">Key Risks<\/span><\/strong><\/h2>\n\n\n\n<ul><li><strong>Offer for Sale component and use of Fresh Issue proceeds<\/strong><br>At the price band, the Offer for Sale of up to 21,613,834 Equity Shares (~\u20b91,275 crore at the Cap, roughly 14% of the total Offer) represents a partial monetisation by promoter-group and investor selling shareholders, and the Company receives no proceeds from it. Of the \u20b98,000 crore Fresh Issue, about \u20b96,127 crore (~77%) is earmarked for debt repayment and the acquisition of a minority stake in Sahyadri, so the primary capital funding incremental growth is limited relative to the headline issue size.<\/li><li><strong>Elevated leverage and finance costs<\/strong><br>Net Debt (including lease liabilities) to Adjusted EBITDA rose to 3.74x in Fiscal 2026 from 2.00x in Fiscal 2025, and total consolidated borrowings stood at \u20b911,185.02 crore as at May 31, 2026, reflecting debt-funded acquisitions (notably the Sahyadri Group). Finance costs jumped ~69% year-on-year to \u20b9864.29 crore in Fiscal 2026 which \u2014 together with higher depreciation and a normalised tax rate \u2014 pushed profit after tax down and compressed RoNW to 10.57%. The planned \u20b95,552.76 crore of debt repayment from Fresh Issue proceeds should ease this, but until deployed, leverage and interest costs continue to weigh on earnings.<\/li><li><strong>Acquisition-led growth with integration and goodwill risk<\/strong><br>A large share of the expansion from 33 hospitals and 9,520 beds (March 31, 2024) to 49 hospitals and 13,037 beds (March 31, 2026) has come through acquisitions, and goodwill on the balance sheet rose to \u20b98,120.57 crore as at March 31, 2026. Realising the targeted margin uplift and integration benefits at recently acquired hospitals (as achieved historically with Columbia Asia) is not assured; delays, underperformance, or any impairment of goodwill could affect returns.<\/li><\/ul>\n\n\n\n<h2><strong><span class=\"has-inline-color has-vivid-cyan-blue-color\">Outlook<\/span><\/strong><\/h2>\n\n\n\n<p>Manipal is positioned to grow alongside a structurally expanding Indian hospital market, underpinned by its #1 bed-capacity scale, entrenched regional and metro leadership, a high-acuity CONGO-R focus, and a proven acquisition-and-integration playbook, with post-issue deleveraging providing a further earnings lever. Near-term watch items include elevated leverage and finance costs, the margin and RoNW compression seen in Fiscal 2026 from acquisition-related costs, and execution and integration of recent acquisitions, notably the Sahyadri Group. The longer-term case rests on rising healthcare penetration, the ongoing shift toward private providers, and the company\u2019s ability to convert its scale and acquisition pipeline into higher-margin, higher-return growth.<\/p>\n\n\n\n<h2><strong><span class=\"has-inline-color has-vivid-cyan-blue-color\">Valuation &amp; View<\/span><\/strong><\/h2>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/07\/image-50.png\"><img loading=\"lazy\" width=\"810\" height=\"157\" src=\"https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/07\/image-50.png\" alt=\"\" class=\"wp-image-35028\" srcset=\"https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2026\/07\/image-50.png 810w, https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2026\/07\/image-50-300x58.png 300w, https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2026\/07\/image-50-768x149.png 768w\" sizes=\"(max-width: 810px) 100vw, 810px\" \/><\/a><\/figure>\n\n\n\n<p>According to the RHP, the company\u2019s listed peers are Apollo Hospitals Enterprise, Fortis Healthcare and Max Healthcare Institute. The peer group is trading at an average P\/E of 70.31x, with the highest being 74.55x and the lowest being 66.15x. At the upper price band, the listing (post-issue) market capitalisation of Manipal will be approximately \u20b977,606 crore, and the company is demanding a P\/E of ~76x on Fiscal 2026 diluted EPS of \u20b97.77 (Pre-issue). When compared to its peers, the issue appears fully valued, sitting at a premium to the peer average. This premium reflects the company\u2019s scale leadership and industry-leading growth, but is set against a modest Fiscal 2026 RoNW of 10.57% and a year in which profit after tax declined; the case for the premium therefore rests on post-issue deleveraging and sustained high-acuity growth rather than on current returns. Based on the above views, we assign a <strong><em>Subscribe<\/em><\/strong> rating to the IPO.<\/p>\n\n\n\n<p><a href=\"https:\/\/www.fundsindia.com\/user\/equity?utm_source=clicks&amp;utm_medium=Blog&amp;utm_campaign=Alpha_Blog_Clicks&amp;utm_term=Blog_CTA\"><img loading=\"lazy\" width=\"300\" height=\"43\" src=\"https:\/\/lh7-rt.googleusercontent.com\/docsz\/AD_4nXceS__GzRS05ubM2opGwf3LkP5BWGjd0wY0nxrnt_yWACJbd9vZEZc0CSi02xWxObbTrv9Xj4_J0fNjfyYBjCMDsCUCQ1VkTZNr6yPlKsknTTO0RAiMxDRumhCaY8KArzlK1m_VJYk1N6Pa1mSpegI?key=HdXWVtHJW8EEqiLEr-EHwsuq\"><\/a><\/p>\n\n\n\n<p><strong>Disclaimer<\/strong>: Investments in the securities market are subject to market risks, read all related documents carefully before investing. Securities quoted here are exemplary, not recommendatory. Please consult your financial advisor before investing. Please note that we do not guarantee any assured returns for the securities quoted here.<\/p>\n\n\n\n<p>Research disclaimer: Investment in the securities market is subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI, and certification from NISM in no way guarantee the performance of the intermediary or provide any assurance of returns to investors.<\/p>\n\n\n\n<p>For more details, please read the <a href=\"https:\/\/fundsindia-marketing-assets.s3.ap-south-1.amazonaws.com\/Disclaimer-final.pdf\">disclaimer.<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Company Overview Manipal Health Enterprises Limited is a pan-India multispecialty hospital operator, running 49 hospitals with 13,037 licensed beds across 14 states and union territories as of March 31, 2026. Its network is concentrated in three key regions \u2014 Karnataka, Maharashtra and Goa, and select states of eastern India (West Bengal, Odisha, Jharkhand and Sikkim) [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":35021,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[59,797],"tags":[745,668,1120,436,1342,1257,614,1246],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v17.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Manipal Health Enterprises - IPO Note - Equity Research Desk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/fundsindia.com\/blog\/equities\/manipal-health-enterprises-ipo-note-equity-research-desk\/35018\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Manipal Health Enterprises - IPO Note - Equity Research Desk\" \/>\n<meta property=\"og:description\" content=\"Company Overview Manipal Health Enterprises Limited is a pan-India multispecialty hospital operator, running 49 hospitals with 13,037 licensed beds across 14 states and union territories as of March 31, 2026. Its network is concentrated in three key regions \u2014 Karnataka, Maharashtra and Goa, and select states of eastern India (West Bengal, Odisha, Jharkhand and Sikkim) [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/fundsindia.com\/blog\/equities\/manipal-health-enterprises-ipo-note-equity-research-desk\/35018\" \/>\n<meta property=\"og:site_name\" content=\"Insights\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/fundsindia\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-28T11:35:22+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-28T11:50:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/07\/1-IPOs-Push.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"512\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Equities Desk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"10 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.fundsindia.com\/blog\/#organization\",\"name\":\"Wealth India Financial Services\",\"url\":\"https:\/\/www.fundsindia.com\/blog\/\",\"sameAs\":[\"https:\/\/www.facebook.com\/fundsindia\"],\"logo\":{\"@type\":\"ImageObject\",\"@id\":\"https:\/\/www.fundsindia.com\/blog\/#logo\",\"inLanguage\":\"en-US\",\"url\":\"https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2018\/07\/download.jpeg\",\"contentUrl\":\"https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2018\/07\/download.jpeg\",\"width\":189,\"height\":200,\"caption\":\"Wealth India Financial Services\"},\"image\":{\"@id\":\"https:\/\/www.fundsindia.com\/blog\/#logo\"}},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.fundsindia.com\/blog\/#website\",\"url\":\"https:\/\/www.fundsindia.com\/blog\/\",\"name\":\"Insights\",\"description\":\"Official blog of FundsIndia.com\",\"publisher\":{\"@id\":\"https:\/\/www.fundsindia.com\/blog\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.fundsindia.com\/blog\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"ImageObject\",\"@id\":\"https:\/\/fundsindia.com\/blog\/equities\/manipal-health-enterprises-ipo-note-equity-research-desk\/35018#primaryimage\",\"inLanguage\":\"en-US\",\"url\":\"https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2026\/07\/1-IPOs-Push.jpg\",\"contentUrl\":\"https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2026\/07\/1-IPOs-Push.jpg\",\"width\":1024,\"height\":512},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/fundsindia.com\/blog\/equities\/manipal-health-enterprises-ipo-note-equity-research-desk\/35018#webpage\",\"url\":\"https:\/\/fundsindia.com\/blog\/equities\/manipal-health-enterprises-ipo-note-equity-research-desk\/35018\",\"name\":\"Manipal Health Enterprises - IPO Note - Equity Research Desk\",\"isPartOf\":{\"@id\":\"https:\/\/www.fundsindia.com\/blog\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/fundsindia.com\/blog\/equities\/manipal-health-enterprises-ipo-note-equity-research-desk\/35018#primaryimage\"},\"datePublished\":\"2026-07-28T11:35:22+00:00\",\"dateModified\":\"2026-07-28T11:50:51+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/fundsindia.com\/blog\/equities\/manipal-health-enterprises-ipo-note-equity-research-desk\/35018#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/fundsindia.com\/blog\/equities\/manipal-health-enterprises-ipo-note-equity-research-desk\/35018\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/fundsindia.com\/blog\/equities\/manipal-health-enterprises-ipo-note-equity-research-desk\/35018#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.fundsindia.com\/blog\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Manipal Health Enterprises &#8211; IPO Note &#8211; Equity Research Desk\"}]},{\"@type\":\"Article\",\"@id\":\"https:\/\/fundsindia.com\/blog\/equities\/manipal-health-enterprises-ipo-note-equity-research-desk\/35018#article\",\"isPartOf\":{\"@id\":\"https:\/\/fundsindia.com\/blog\/equities\/manipal-health-enterprises-ipo-note-equity-research-desk\/35018#webpage\"},\"author\":{\"@id\":\"https:\/\/www.fundsindia.com\/blog\/#\/schema\/person\/78222a5d6aef66b1f386dfa767382656\"},\"headline\":\"Manipal Health Enterprises &#8211; IPO Note &#8211; Equity Research Desk\",\"datePublished\":\"2026-07-28T11:35:22+00:00\",\"dateModified\":\"2026-07-28T11:50:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/fundsindia.com\/blog\/equities\/manipal-health-enterprises-ipo-note-equity-research-desk\/35018#webpage\"},\"wordCount\":1611,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.fundsindia.com\/blog\/#organization\"},\"image\":{\"@id\":\"https:\/\/fundsindia.com\/blog\/equities\/manipal-health-enterprises-ipo-note-equity-research-desk\/35018#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2026\/07\/1-IPOs-Push.jpg\",\"keywords\":[\"FundsIndia Equity Research\",\"fundsindia ipo\",\"healthcare stock\",\"IPO\",\"manipal hospital\",\"portfoliomanagement\",\"stock market\",\"wealth management\"],\"articleSection\":[\"Equity Research\",\"IPO Note\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/fundsindia.com\/blog\/equities\/manipal-health-enterprises-ipo-note-equity-research-desk\/35018#respond\"]}]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.fundsindia.com\/blog\/#\/schema\/person\/78222a5d6aef66b1f386dfa767382656\",\"name\":\"Equities Desk\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\/\/www.fundsindia.com\/blog\/#personlogo\",\"inLanguage\":\"en-US\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/2620d09063050fc426411ab6ea46fc72?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/2620d09063050fc426411ab6ea46fc72?s=96&d=mm&r=g\",\"caption\":\"Equities Desk\"},\"sameAs\":[\"http:\/\/www.fundsindia.com\"],\"url\":\"https:\/\/www.fundsindia.com\/blog\/author\/equities-desk\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Manipal Health Enterprises - IPO Note - Equity Research Desk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/fundsindia.com\/blog\/equities\/manipal-health-enterprises-ipo-note-equity-research-desk\/35018","og_locale":"en_US","og_type":"article","og_title":"Manipal Health Enterprises - IPO Note - Equity Research Desk","og_description":"Company Overview Manipal Health Enterprises Limited is a pan-India multispecialty hospital operator, running 49 hospitals with 13,037 licensed beds across 14 states and union territories as of March 31, 2026. Its network is concentrated in three key regions \u2014 Karnataka, Maharashtra and Goa, and select states of eastern India (West Bengal, Odisha, Jharkhand and Sikkim) [&hellip;]","og_url":"https:\/\/fundsindia.com\/blog\/equities\/manipal-health-enterprises-ipo-note-equity-research-desk\/35018","og_site_name":"Insights","article_publisher":"https:\/\/www.facebook.com\/fundsindia","article_published_time":"2026-07-28T11:35:22+00:00","article_modified_time":"2026-07-28T11:50:51+00:00","og_image":[{"width":1024,"height":512,"url":"https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2026\/07\/1-IPOs-Push.jpg","type":"image\/jpeg"}],"twitter_misc":{"Written by":"Equities Desk","Est. reading time":"10 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Organization","@id":"https:\/\/www.fundsindia.com\/blog\/#organization","name":"Wealth India Financial Services","url":"https:\/\/www.fundsindia.com\/blog\/","sameAs":["https:\/\/www.facebook.com\/fundsindia"],"logo":{"@type":"ImageObject","@id":"https:\/\/www.fundsindia.com\/blog\/#logo","inLanguage":"en-US","url":"https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2018\/07\/download.jpeg","contentUrl":"https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2018\/07\/download.jpeg","width":189,"height":200,"caption":"Wealth India Financial Services"},"image":{"@id":"https:\/\/www.fundsindia.com\/blog\/#logo"}},{"@type":"WebSite","@id":"https:\/\/www.fundsindia.com\/blog\/#website","url":"https:\/\/www.fundsindia.com\/blog\/","name":"Insights","description":"Official blog of FundsIndia.com","publisher":{"@id":"https:\/\/www.fundsindia.com\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.fundsindia.com\/blog\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"ImageObject","@id":"https:\/\/fundsindia.com\/blog\/equities\/manipal-health-enterprises-ipo-note-equity-research-desk\/35018#primaryimage","inLanguage":"en-US","url":"https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2026\/07\/1-IPOs-Push.jpg","contentUrl":"https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2026\/07\/1-IPOs-Push.jpg","width":1024,"height":512},{"@type":"WebPage","@id":"https:\/\/fundsindia.com\/blog\/equities\/manipal-health-enterprises-ipo-note-equity-research-desk\/35018#webpage","url":"https:\/\/fundsindia.com\/blog\/equities\/manipal-health-enterprises-ipo-note-equity-research-desk\/35018","name":"Manipal Health Enterprises - IPO Note - Equity Research Desk","isPartOf":{"@id":"https:\/\/www.fundsindia.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/fundsindia.com\/blog\/equities\/manipal-health-enterprises-ipo-note-equity-research-desk\/35018#primaryimage"},"datePublished":"2026-07-28T11:35:22+00:00","dateModified":"2026-07-28T11:50:51+00:00","breadcrumb":{"@id":"https:\/\/fundsindia.com\/blog\/equities\/manipal-health-enterprises-ipo-note-equity-research-desk\/35018#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/fundsindia.com\/blog\/equities\/manipal-health-enterprises-ipo-note-equity-research-desk\/35018"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/fundsindia.com\/blog\/equities\/manipal-health-enterprises-ipo-note-equity-research-desk\/35018#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.fundsindia.com\/blog"},{"@type":"ListItem","position":2,"name":"Manipal Health Enterprises &#8211; IPO Note &#8211; Equity Research Desk"}]},{"@type":"Article","@id":"https:\/\/fundsindia.com\/blog\/equities\/manipal-health-enterprises-ipo-note-equity-research-desk\/35018#article","isPartOf":{"@id":"https:\/\/fundsindia.com\/blog\/equities\/manipal-health-enterprises-ipo-note-equity-research-desk\/35018#webpage"},"author":{"@id":"https:\/\/www.fundsindia.com\/blog\/#\/schema\/person\/78222a5d6aef66b1f386dfa767382656"},"headline":"Manipal Health Enterprises &#8211; IPO Note &#8211; Equity Research Desk","datePublished":"2026-07-28T11:35:22+00:00","dateModified":"2026-07-28T11:50:51+00:00","mainEntityOfPage":{"@id":"https:\/\/fundsindia.com\/blog\/equities\/manipal-health-enterprises-ipo-note-equity-research-desk\/35018#webpage"},"wordCount":1611,"commentCount":0,"publisher":{"@id":"https:\/\/www.fundsindia.com\/blog\/#organization"},"image":{"@id":"https:\/\/fundsindia.com\/blog\/equities\/manipal-health-enterprises-ipo-note-equity-research-desk\/35018#primaryimage"},"thumbnailUrl":"https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2026\/07\/1-IPOs-Push.jpg","keywords":["FundsIndia Equity Research","fundsindia ipo","healthcare stock","IPO","manipal hospital","portfoliomanagement","stock market","wealth management"],"articleSection":["Equity Research","IPO Note"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/fundsindia.com\/blog\/equities\/manipal-health-enterprises-ipo-note-equity-research-desk\/35018#respond"]}]},{"@type":"Person","@id":"https:\/\/www.fundsindia.com\/blog\/#\/schema\/person\/78222a5d6aef66b1f386dfa767382656","name":"Equities Desk","image":{"@type":"ImageObject","@id":"https:\/\/www.fundsindia.com\/blog\/#personlogo","inLanguage":"en-US","url":"https:\/\/secure.gravatar.com\/avatar\/2620d09063050fc426411ab6ea46fc72?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/2620d09063050fc426411ab6ea46fc72?s=96&d=mm&r=g","caption":"Equities Desk"},"sameAs":["http:\/\/www.fundsindia.com"],"url":"https:\/\/www.fundsindia.com\/blog\/author\/equities-desk"}]}},"jetpack_featured_media_url":"https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2026\/07\/1-IPOs-Push.jpg","_links":{"self":[{"href":"https:\/\/www.fundsindia.com\/blog\/wp-json\/wp\/v2\/posts\/35018"}],"collection":[{"href":"https:\/\/www.fundsindia.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fundsindia.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fundsindia.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fundsindia.com\/blog\/wp-json\/wp\/v2\/comments?post=35018"}],"version-history":[{"count":3,"href":"https:\/\/www.fundsindia.com\/blog\/wp-json\/wp\/v2\/posts\/35018\/revisions"}],"predecessor-version":[{"id":35031,"href":"https:\/\/www.fundsindia.com\/blog\/wp-json\/wp\/v2\/posts\/35018\/revisions\/35031"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fundsindia.com\/blog\/wp-json\/wp\/v2\/media\/35021"}],"wp:attachment":[{"href":"https:\/\/www.fundsindia.com\/blog\/wp-json\/wp\/v2\/media?parent=35018"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fundsindia.com\/blog\/wp-json\/wp\/v2\/categories?post=35018"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fundsindia.com\/blog\/wp-json\/wp\/v2\/tags?post=35018"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}